SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA
77% Revenue Growth in Evolve® Rodent Birth Control™ Products
Strong Cash Balance and Progress Toward Profitability
SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025.
Q3 2025 Financial Highlights
Q3 2025 Operational and Strategic Highlights
Commentary
"We are pleased to report another quarter of strong results, reflecting the growing adoption of our Evolve product line," commented Joel Fruendt, CEO of SenesTech. "Our multi-channel distribution strategy continues to take hold, with meaningful contributions from e-commerce, municipal programs, retail partners, and pest management professionals. These results are a credit to careful planning, disciplined execution, and a continued focus on efficiency, which together supported healthy margins and our strongest Adjusted EBITDA to date."
"With a strong balance sheet, highlighted by more than $10 million in funding available at the end of September, we intend to pursue profitable growth moving forward. This positions us to work toward achieving our breakeven goals and to realize the long-term potential of introducing a novel product category into the pest control market," Fruendt concluded.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. However, this measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
Conference Call Details
Date: Monday, November 10, 2025.
Time: 5:00 p.m. ET.
Webcast: https://app.webinar.net/Pj7rLgb3Ew4.
Webcast Replay: Available for 90 days on the Company's website.
About SenesTech
We are committed to improving the health of the world by humanely managing animal pest populations through our expertise in fertility control. We invented ContraPest®, the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve Rat and Evolve Mouse, EPA-designated minimum risk contraceptives for rodents, reflecting our mission to provide products that are proactive, safe and sustainable. ContraPest and Evolve are intended to fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.
For more information visit https://senestech.com/.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our belief that our cash and short-term investments of $10.2 million provide the Company with a solid operating runway; our belief that Evolve Rat and Evolve Mouse continue to gain traction among pest management professionals and consumers; our expectation for accelerated growth across e-commerce sites; our expectation for additional municipal deployments that are underway or planned; our belief that future growth is expected from retailers who begin with e-commerce before expanding to in-store offerings; our diverse multi-channel distribution strategy; our intention to pursue profitable growth moving forward; our belief that our cash balance positions us to work toward achieving our breakeven goals and to realize the long-term potential of introducing a novel product category into the pest control market; our mission to provide products that are proactive, safe and sustainable; and our belief that ContraPest and Evolve are intended to fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management.
Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to maintain compliance with Nasdaq's continued listing requirements; regulatory approval and regulation of our products; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACT:
Investors: Robert Blum, Lytham Partners, LLC, (602) 889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., (928) 779-4143
SENESTECH, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)
September 30,
2025
December 31,
2024
ASSETS
Current assets:
Cash and cash equivalents
$ 7,278
$ 1,307
Short-term investments
2,970
—
Accounts receivable, net
454
335
Inventory, net
767
794
Prepaid expenses and other current assets
313
377
Total current assets
11,782
2,813
Right to use asset, operating lease
2,377
—
Property and equipment, net
429
407
Other noncurrent assets
36
58
Total assets
$ 14,624
$ 3,278
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 238
$ 215
Accrued expenses
333
278
Current portion of operating lease liability
95
—
Current portion of notes payable
60
56
Deferred revenue
22
12
Total current liabilities
748
561
Operating lease liability, less current portion
2,368
—
Notes payable, less current portion
160
206
Total liabilities
3,276
767
Stockholders' equity:
Common stock
5
1
Additional paid-in capital
152,019
138,607
Accumulated deficit
(140,676)
(136,097)
Total stockholders' equity
11,348
2,511
Total liabilities and stockholders' equity
$ 14,624
$ 3,278
SENESTECH, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Revenues, net
$ 690
$ 482
$ 1,800
$ 1,356
Cost of sales
257
167
645
657
Gross profit
433
315
1,155
699
Operating expenses:
Research and development
400
451
1,245
1,288
Selling, general and administrative
1,380
1,411
4,534
4,403
Total operating expenses
1,780
1,862
5,779
5,691
Loss from operations
(1,347)
(1,547)
(4,624)
(4,992)
Other income, net
49
34
45
63
Net loss
$ (1,298)
$ (1,513)
$ (4,579)
$ (4,929)
Weighted average shares outstanding — basic and diluted
4,668,009
729,400
2,619,841
586,628
Loss per share — basic and diluted
$ (0.28)
$ (2.07)
$ (1.75)
$ (8.40)
SENESTECH, INC.
Itemized Reconciliation Between Net Loss and Adjusted EBITDA (non-GAAP)
(In thousands)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Net loss (as reported, GAAP)
$ (1,298)
$ (1,513)
$ (4,579)
$ (4,929)
Non-GAAP adjustments:
Interest income, net
(49)
(5)
(45)
(33)
Stock-based compensation expense
47
73
228
246
Depreciation expense
20
42
103
115
Non-cash operating lease expense (benefit)
49
(2)
87
(5)
Severance costs
—
13
27
13
Gain on sale of property and equipment
—
(28)
—
(28)
Total non-GAAP adjustments
67
93
400
308
Adjusted EBITDA loss (non-GAAP)
$ (1,231)
$ (1,420)
$ (4,179)
$ (4,621)
SOURCE SenesTech, Inc.